Appendix A: Accommodating known times of absorption in observed data likelihood
The backward function is initialized with β tn (u) = 1, and the recursion for k = 1, . . . , n − 1 is
Observed data likelihood
The observed data likelihood (Section 2.4, eq 1 of the main text) is P (o, τ , h) = u α tn (u), via the forward algorithm; by the backward algorithm, it is P (o, τ , h) = u β t 1 (u)e(u, o 1 )ν h 1 π x 1 (h 1 ). The forward and backward recursions make the likelihood evaluation practical because, similarly to the standard HMM forward-backward algorithm, the algorithmic complexity of both recursions is O(ns 2 ).
Hidden state smoothing probabilities
One can generalize the forward and backward functions to an arbitrary time t. That is, we can define α t (u) = P [o 1:k , τ (1, k), h 1:k , X(t) = u], for t ∈ [t k , t k+1 ], which is given by
Similarly, we define β t (u) = P [o k+1:n , τ (k + 1, n), h k+1:n |X(t) = u], for t ∈ [t k−1 , t k ], which is given by
The general versions of the forward and backward functions also allow us to calculate the smoothing probability P[X(t) = i|o, τ , h] for any t ∈ [t 1 , t n ], which predicts the hidden disease state at an arbitrary time conditional on the observed data. This probability is given by P[X(t) = i|o, τ , h] = β t (i)α t (i) P(o, τ , h) .
(B-1)
Appendix C: Expectation step
To compute the expectation step (E-step) for the EM algorithm, we note that an individual's loglikelihood contribution (eq. (2) in main manuscript) is additive across time intervals T l = [t l , t l+1 ].
Thus,
Computing the E-step therefore requires conditional expectations of the complete data sufficient statistics across T l . Conditional expectations for z i , o T l (i, j), and u T l (i) are computed using the smoothing probabilities P(X l = m|o, τ , h) (B-1). Hence,
,
Note that the sum in the last set of identities is over 2 to n, as the first time should not be considered an observed DDO event.
Expectations of CMTC sufficient statistics
(C-1) This follows due to conditional independence of X(t) on [t l , t l+1 ] given knowledge of the joint disease and DDO process at the interval endpoints. The task of computing the expectation can be broken down into computing "inner" expectations E [C T l |X l = a, X l+1 = b, H l+1 = h l+1 ] and "outer" expectations. We describe the "inner" and "outer" expectations in turn.
Inner expectations for CTMC sufficient statistics
The formulae for the "inner expectations" are based on conditional expectations for CTMC sufficient statistics with absorbing states (Asmussen et al., 1996) . We derive the desired quantities by considering conditional expectations of sufficient statistics C = n ij (t) or C = d t (i) for a generic homogeneous CTMC X(t) on the interval [0, t], conditional on X(t) at interval endpoints and the informative observation status h t at time t.
To obtain these expectations, recall that W a0,b1 is the first passage time of the bivariate CTMC Y (t) = (X(t), N (t)) from state (a,0) to state (b,1). W a0,b1 has the same distribution as the time to absorption in state (b, 1) of the auxiliary process Y (t), given Y (0) = (a, 0) and has survival function S ab (t) = exp(Λ − Q) ab and density function f ab (t) = exp [(Λ − Q) t] ab q b (Section 2.1 in the main manuscript). We will use conditional expectation formulae applicable to Y (t) to derive the desired quantities.
When the endpoint t is a scheduled visit (h t = 0), we seek the conditional expectation
Our bivariate representation of the process Y (t) enables us to use standard methods for computing expectations for CTMCs (Hobolth and Jensen, 2011) . Thus, for C = d t (i), the numerator in C-2 is the joint expectation
and for C = n t (i, j), the joint expectation
When t corresponds to a DDO (h i = 1), we seek the conditional expectation
To calculate the numerator, we employ expectation formulae derived for CTMCs with absorbing states (Asmussen et al., 1996) . For C = d t (i), the numerator in (C-3) is given by the differentiated joint expectation
and for C = n t (i, j), by
where
We also need to consider the special case of computing conditional expectations for d t (i) and n t (i, j) when the interval endpoint t corresponds to a known absorption time in the disease process, such as a time of death. Let A be the set of all absorbing states in S. Treating DDO events as a competing risk, suppose W a0,k0 is the time of absorption of Y (t) in state k ∈ A, given Y (0) = (a, 0), with density g ak (t) = j ∈A S ij (t)λ jk . In this case, we need the conditional expectation
When the complete-data statistic of interest is C = d t (i), the numerator in C-4 is the differentiated joint expectation
For C = n t (i, j), the numerator in C-4 is the differentiated joint expectation
One can use eigenvalue decomposition or the uniformization approach to computing the integrals in each of the joint expectation formulae (Hobolth and Jensen, 2011) . Our implementation uses the efficient matrix-based methods from (Minin and Suchard, 2008) .
Outer expectations for CTMC sufficient statistics
After computing the "inner expectations," using the described formulae, one can compute "outer" expectations (C-1) for sufficient statistics
on the interval T l using Baum-Welch's bivariate smoothing probabilities
Thus, the expression for the conditional expectation of the complete data sufficient statistic C T across the entire time interval Figures D-1A and D-1B) , including DDO rates, fixed observation times, and misclassification probabilities. These data specifications pertain to experiments summarized in Figure 2 in the main text and in Figure D- Figure D-1C) , including DDO rates, fixed observations, and misclassification probabilities. Notation: q I/C = q I = q C and e(H, I/C) = e(H, I) = e(H, C). These data specifications pertain to experiments summarized in Figure D- 
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Figure D-2: Functional box plots for simulated data estimates of cumulative incidence for disease events I and C in the latent CTMC competing risks model ( Figure D-1C. ) Discretely observed data were generated from the disease trajectories according to informative observation times from a DDO model with q H1 = q H2 = .25 and q I = q C = 2, and varying proportions of supplemental non-informative times. Observations had 70% sensitivity and 98% specificity, corresponding to mammography data. See Table D Table D -1 for further details. Data are fit with correctly specified multistate-DDO or panel models. These result demonstrate the gains in precision in hazard estimates via jointly modeling informative sampling times in the presence of misclassification error.
Simulation studies examining estimated covariate effects on disease transition parameters
These simulations used the competing risks latent CTMC disease model as their disease model framework ( Figure D-1C) . Informative observation times were generated at a rate of 2/year in states I and C, and .25/year in states H 1 , and H 2 . Each dataset consisted of 500 individuals, observed at informative sampling times between t = 0 and t = 8 years. We generated a binary covariate, X, and assumed that relative to those with X=0, those with X=1 had the log intensity rates H 1 → C and H 2 → C increased by 1.5, and the H 1 → I and H 2 → I transitions reduced by 1.5. We then fit a correctly specified multistate-DDO model or an analogous, but incorrectly specified, panel model to 100 simulated datasets.
The results summarizing the estimates of these two parameters (denoted β 1 and β 2 , with data generating values of 1.5 and -1.5, respectively) are summarized in Table D -3. Also shown are the intercept terms for the intensity rates. For the correctly specified models, the estimates of β 1 and β 2 and their standard errors demonstrate little apparent bias, and the coverage of 95% confidence intervals was close to the nominal 95%. Interestingly, the estimates from the panel model are similar in sign, and not too far off in magnitude, to their data-generating values, despite the obvious bias of other estimates of intensity parameters in the latent model. Moreover, the confidence interval coverage for the estimated covariate effects is not too far from the nominal 95%.
Simulation studies examining usefulness of Bayesian information criterion for model selection
To verify the usefulness of the BIC in latent state selection, we have conducted simulation experiments. In these studies, we used the competing risks latent CTMC disease model ( Figure D-1C) and generated informative sampling times with rates of 2/year in states I and C and .25/year in states H 1 , and H 2 . We generated 50 data sets with 1000 individuals each and fit models that either correctly or incorrectly specified the latent CTMC disease and informative sampling time models. The alternative, incorrect models, varied either the disease model structure or the informative sampling time model. Table D-4 provides details of the additional models fit to the data. After fitting each model to the simulated data, we calculated and ranked the BIC for each of the models fit to the data. Across each of the 50 datasets, the ranking of the BIC was consistent: BIC was lowest for the correctly specified model (Model 3, Table D-4), followed by Models 4, 5, 1, and 2. Thus, using the criterion of selecting a model based on the lowest BIC, the correctly specified model was selected for 50/50 simulated datasets.
Appendix E: Second Breast Cancer Event Application

Mammography and biopsy outcomes
Mammograms were positive if the BI-RADS (Breast Imaging-Reporting and Data System) score was 0="more imaging needed," 4="suspicious abnormality," 5="highly suggestive of malignancy," or 6="known malignancy" American College of Radiology (2003) . Biopsies with a result of invasive 
Latent CTMC (2 states) q H 1 = q H 2 10 5 Latent CTMC (3 states) q H 1 = q H 2 = q H 3 , q I = q C 13 malignancy or ductal carcinoma in situ (DCIS) were considered positive; negative findings included benign growths and benign hyperplasias.
Dataset exclusions
There were 4,133 women with primary unilateral breast cancers diagnosed from 1994-2009 who subsequently received mammography at Group Health. We applied sequential exclusions to obtain an analysis dataset. We excluded women with a mammographically-detectable SBCE within 180 days following the primary breast cancer diagnosis (N=94), since events prior to that time likely reflect progression of the primary disease. We also excluded women if they had a biopsy record not preceded by a mammogram within the preceding 100 days (N=352), as well as those with any missing laterality for mammograms or biopsy procedures (N=424), and those missing any of the covariates of interest (N=327). In total, these exclusions reduced the dataset from 4,133 to 2,936 women, removing 49% percent of ipsilateral cases, 32% of contralateral cases, 37% of those who died prior to an SBCE, and 27% of those who were alive and SBCE-free at the time they were last seen. More ipsilateral cases were dropped since they were more likely to have biopsies not preceded by mammograms within the study period.
Sample characteristics
The 2,936 women in the sample used for analysis, as well as the 1,197 excluded from the sample, are described in Table E -1. The sample was predominantly white (84.7%, N=2,488), with a median age of 61 at primary breast cancer diagnosis (IQR 52, 71) . Approximately one fifth of the sample had a stage 0 (DCIS) primary breast cancer (18.6%, N=548), whereas half had stage 1 (49.6%, N=1,456), and the rest, stage 2 or higher. The main difference between included and excluded women is that excluded individuals were more likely to have stage 2 or higher cancer. This is related to our exclusion of individuals with biopsies not preceded by mammograms within the study period being more likely to have advanced stage primary breast cancer. Figure E-3: Empirical cumulative incidence estimates for diagnosis of ipsilateral and contralateral SBCEs and death prior to SBCE, stratified by covariate levels.
